BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

 
An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor efficacy against melanoma
YE QIN1,*, MULAN WEI1,3, XUJIE LIU2, CHUNYU CAO1, JIANLIN YANG1, YAFENG LV1, JIAOJIAO HUANG1, YANLIN WANG1
1Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Three Gorges University Medical College,
2Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College,
3Department of Pathology, Yiling Hospital
Abstract
Recent studies have shown that PD-1/PD-L1 checkpoint blockade is a dramatic therapy for melanoma through enhancing antitumor immune activity. Currently, major strategies for PD-1/PD-L1 blockade have mainly focused on the use of antibodies and compounds. For seeking an alternative approach, it is of interest to employ endogenous proteins as blocking agents. Considering the facts that extracellular domain of PD-1 (ePD1) includes the specific binding site with PD-L1, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) which consists of bivalent variable fragment (dFv) of MMP-2/9-targeted antibody and ePD1. Furthermore, the melanoma-binding intensity and antitumor activity were investigated. As shown, intense and selective binding capability of the protein dFv-ePD1 to human melanoma specimens was confirmed by tissue microarray. In addition, dFv-ePD1 suppressed significantly the migration and invasion of mouse melanoma cells B16-F1 and displayed the cytotoxicity to cancer cells in vitro. Notably, dFv-ePD1 significantly inhibited the growth of mouse melanoma B16-F1 tumor in mice and in vivo fluorescence imaging showed that dFv-ePD was gradually accumulated in B16-F1 tumor, whose fluorescence intensity at tumor site was stronger than that of dFv. The study indicates that the recombinant protein dFv-ePD1 have an intensive melanoma-binding capability and exert potent therapeutic efficacy against melanoma. The novel format of PD-L1-blocked agent may play an active role in antitumor immunotherapy.
Abstract, Accepted Manuscript(in press) [Submitted on April 10, 2018, Accepted on June 11, 2018]
  Copyright © KSBMB. All rights reserved. / Powered by INFOrang.co., Ltd